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AbstrAct:
The glioblastoma genome displays remarkable chromosomal aberrations, which 
harbor  critical  glioblastoma-specific  genes  contributing  to  several  oncogenetic 
pathways. To identify glioblastoma-targeted genes, we completed a multifaceted 
genome-wide  analysis  to  characterize  the  most  significant  aberrations  of  DNA 
content occurring in glioblastomas.  We performed copy number analysis of 111 
glioblastomas by Digital Karyotyping and Illumina BeadChip assays and validated our 
findings using data from the TCGA (The Cancer Genome Atlas) glioblastoma project.  
From this study, we identified recurrent focal copy number alterations in 1p36.23 
and 4p16.3. Expression analyses of genes located in the two regions revealed genes 
which are dysregulated in glioblastomas. Specifically, we identify EGFR negative 
regulator, ERRFI1, within the minimal region of deletion in 1p36.23. In glioblastoma 
cells with a focal deletion of the ERRFI1 locus, restoration of ERRFI1 expression 
slowed cell migration. Furthermore, we demonstrate that TACC3, an Aurora-A 
kinase substrate, on 4p16.3, displays gain of copy number, is overexpressed in a 
glioma-grade-specific  pattern,  and  correlates  with  Aurora  kinase  overexpression 
in glioblastomas. Our multifaceted genomic evaluation of glioblastoma establishes 
ERRFI1 as a potential candidate tumor suppressor gene and TACC3 as a potential 
oncogene, and provides insight on targets for oncogenic pathway-based therapy.
Abbreviations used:  TACC3, transforming, acidic coiled-coil containing protein 3; FGFR3, fibroblast growth factor receptor 3; 
AURKA, aurora kinase A; AURKB, aurora kinase B; AURKC, aurora kinase C; ERRFI1, ERBB receptor feedback inhibitor 1; EGFR, epi-
dermal growth factor receptor; ERBB, epidermal growth factor receptor family; TCGA, The Cancer Genome Atlas; CNV, copy 
number variation; SAGE, Serial Analysis of Gene Expression; Q-PCR, quantitative polymerase chain reaction; FCS, fetal calf serum.   Oncotarget 2010; 1: 265-277 266 www.impactjournals.com/oncotarget
INtrODUctION
Cancer cells undergo continuous acquisition of 
heritable genetic variation, manifested as mutations of 
single base pairs, large or small deletions or insertions, 
chromosomal translocations, and gain or loss of entire 
chromosomal regions [1, 2]. The accumulation of these 
somatic genomic changes results in a highly heterogeneous 
and complex cancer genome.  Glioblastoma is the most 
aggressive and frequently occurring type of brain tumor [3, 
4].  Recent comprehensive analyses have opened the door 
to understanding the genetic and molecular alterations 
that characterize the glioblastoma genome.  These studies 
identified  sequence  mutations  and  alterations  of  DNA 
copy number, gene expression, and methylation status 
that may contribute to a distinct network of oncogenic 
signaling pathways, including receptor tyrosine kinase 
(RTK), growth factor and phosphatidylinositol-3-OH 
kinase (PI3K), p53 and retinoblastoma (RB1) pathways 
[5, 6].
Identification  of  a  coding  sequence  alteration, 
amplification,  or  homozygous  deletion  can  help  define 
unequivocal driver genetic alterations in cancers [6].   
Several genes in the central glioblastoma pathways were 
identified  through  dramatic  copy  number  alterations, 
such as amplification of the oncogenes, EGFR, c-MYC, 
CDK4, PDGFRA, MDM2, and MDM4, and deletion of the 
tumor suppressor genes, CDKN2A, CDKN2B, and PTEN 
[5-9].  Recent studies have validated the significance of 
well-known copy number alterations and have proposed 
additional candidates which may contribute to the 
development of glioblastomas [5, 6, 10-12].  Conversely, 
several core glioblastoma genes have been found to 
be exclusively altered by sequence mutation, such as   
PI(3)K, RAS, ERBB2, and IDH1/ IDH2 [5, 13].  However, 
a large proportion of recognized glioblastoma driver 
genes, including EGFR, TP53, CDKN2A, PTEN, NF1 
and RB1, are targeted by both sequence and copy number 
alterations.  In addition, gene expression signatures, which 
are an essential component of global genomic studies, have 
been used to exploit disease-specific signaling pathways 
and as clinical prognostic factors in many cancers [14-
17].  However, despite major advancements, the current 
understanding of glioblastoma genetics is still inadequate, 
and additional molecular targets are urgently needed to be 
used in the development of clinically proven therapies.  
In this study, we used Digital Karyotyping (DK) and 
Illumina BeadChip assays (Illumina, Inc., San Diego, CA) 
to identify genomic loci that are recurrently targeted by 
focal copy number alterations in 111 glioblastomas. Using 
these data and data from TCGA, we identified frequent 
gene copy number changes in1p36.23 and 4p16.3. We 
further demonstrated that ERRFI1 and TACC3 in 1p36.23 
and 4p16.3, respectively, are  potential glioblastoma-
targeted genes. 
rEsULts
Detection of focal copy number alterations by DK 
and Illumina beadchips
DK is a highly quantitative copy number analysis 
platform that has previously been used to identify copy 
number events in human cancers, including glioblastomas 
[18-20]. Analysis  of  27  glioblastoma  samples  revealed 
52 high-copy amplification events ranging from 98kb to 
6.8Mb with 12 to 205 copies per nucleus.  The targeted 
genes within those regions include gain of EGFR, CDK4, 
PDGFRA, MDM2, and MDM4 (Supplemental Table S1).   
In  addition,  we  identified  120  regions  of  homozygous 
deletion, ranging from 100kb to 5.1Mb.  The most common 
loss is on chromosome 9p21, where tumor suppressor 
genes CDKN2A and CDKN2B are located (Supplemental 
Table S2).
Illumina BeadChips in conjunction with the Infinium 
assay have also been effectively used to examine copy 
number variations in human cancers at high-throughput 
levels [5, 6, 20].  First, using the highly quantitative 
DK  data,  we  optimized  the  criteria  for  defining  focal 
high-copy amplifications and homozygous deletions for 
Illumina  high-density  SNP  arrays.    Two  glioblastoma 
samples, xenograft H456 and primary tumor TB2607, 
were analyzed by both DK and Illumina high-density SNP 
arrays. Using DK as a standard, we identified the values 
and filtering criteria (stated in Materials and Methods) 
that  faithfully  reveal  amplifications  and  deletions  from 
the data produced by the Illumina BeadChips.  We 
generated Illumina high-density SNP array profiles from 
84 glioblastomas samples.  As controls, we also analyzed 
genomic DNA from normal adult and fetal brain and 3 
matching blood specimens from glioblastoma patients.  In 
total, we identified 474 focal gain events (Supplemental 
Table S3) and 1540 focal loss events (Supplemental Table 
S4).
Of the genomic copy number profiles from a total 
of 111 glioblastoma samples assessed by DK or Illumina 
BeadChips, we identified a high degree of heterogeneity 
and copy number instability across the glioblastoma 
genomes (Figure 1A).  Despite heterogeneity, we detected 
several regions which are recurrently gained or lost in 
glioblastomas (Figure 1B, C).  The two most prevalent 
focal  amplifications  were  the  EGFR and CDK4 loci, 
occurring in 42% and 12% of all cases, respectively.  The 
two most prevalent focal deletions were the CDKN2A/B 
and 1p36 loci, occurring in 40% and 9% of all samples, 
respectively. Additionally, we detected multiple intragenic 
homozygous deletions within large genes, including 
LRP1B, WWOX, and A2BP1.Oncotarget 2010; 1: 265-277 267 www.impactjournals.com/oncotarget
ErrFI1 on 1p36 is a candidate tumor suppressor 
gene, whose products regulate glioblastoma cell 
migration
In addition to the well-characterized glioblastoma 
genes,  the  most  striking  genomic  changes  identified 
in our analysis were recurrent focal copy number 
changes on 1p36 and 4p16.  Focal deletions of 1p36 
have been previously reported to occur in numerous 
cancer types, including glioblastoma, neuroblastoma, 
oligodendroglioma, and colorectal, lung, and breast 
cancer [21-23].  We detected focal homozygous deletions 
on 1p36 in 9/111 of our glioblastoma samples.  With the 
addition of samples from the TCGA glioblastoma data set, 
we mapped 1p36 deletions in a comprehensive data set 
of a total 430 glioblastomas and found they occurred in 
two distinct minimal deleted regions (MDRs) on 1p36.32 
(Figure 2) and on 1p36.23 (Figure 3).  
    Glioblastoma cell line H542 presented a 
homozygous deletion at 1p36.32 (Figure 2A).  We mapped 
the 1p36.32 deletion in H542 by quantitative real-time 
PCR (Q-PCR) and found that this region contained TP73, 
KIAA0495, CCDC27, LOC388588, LRRC47, KIAA0562, 
DFFB,  C1orf174,  LOC100133612, and LOC284661 
(Figure 2B, Supplemental Table 5).  Further analysis 
of additional samples with 1p36.32 deletions revealed 
an  overlapped  MDR  containing  DFFB,  C1orf174, and 
LOC100133612 (Figure 2B). 
Cytoband 1p36.23 harbors the most frequently 
deleted region (Figure 3) on 1p36 in glioblastomas. Two 
glioblastoma cell lines, H423 and H502, each contained a 
single focal deletion in 1p36.23 (Figure 3A).  We further 
mapped the 1p36.23 deletions in the two cell lines by 
Q-PCR.  The deleted region contains multiple genes, 
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Figure 1: Focal high copy number gains and homozygous deletions in glioblastomas. Copy number analysis using DK and 
Illumina BeadChips revealed gains (indicated by green) and losses (indicated by red) spanning the genome of glioblastomas.  (A) Glioblastoma 
copy number karyotype generated utilizing Nexus Copy Number Professional Software (BioDiscovery Inc.). The most common regions for (B) 
focal deletion and (C) focal gain of copy number in 111 glioblastomas.  Loci are identified with reported tumor suppressor genes and oncogenes 
if available.Oncotarget 2010; 1: 265-277 268 www.impactjournals.com/oncotarget
including  CAMTA1,  VAMP3,  PER3,  UTS2,  TNFRSF9, 
PARK7, ERRFI1, SLC45A1, RERE, ENO1, CA6, SLC2A7 
and SLC2A5 (Figure 3B, Supplemental Table 6).  With the 
addition of TCGA glioblastoma samples, we found that 
15/430 glioblastomas contain homozygous deletions in 
1p36.23.  Further analysis revealed the most commonly 
deleted region contains a single gene, ERRFI1 (Figure 
3B).  
ERRFI1 is a candidate tumor suppressor which 
functions in normal cells as a negative regulator of EGFR 
and the ErbB family [24-26]. We measured ERRFI1 
mRNA levels in a panel of 62 glioblastoma samples and 
detected downregulation of ERRFI1 expression in 34% of 
the samples tested (Figure 4A).   
We further investigated the possible pathogenic 
function of ERRFI1 in glioblastoma cells.  Glioblastoma 
cell line H423 harbors a homozygous deletion of ERRFI1 
and did not express endogenous ERRFI1 (Figure 4A). We 
transfected H423 cells with pCMV-6-entry-ERRFI1 and 
performed wound-healing experiments on the transfected 
cells.  Compared to cells transfected with a control vector, 
H423 cells with ERRFI1 expression had impaired wound 
healing (Figure 4B).  Furthermore, we conducted trans-
well assays and demonstrated that H423 cells with ERRFI1 
expression had a lower rate of trans-well migration than 
control cells (Figure 4C). 
tAcc3 on 4p16.3 is overexpressed and correlates 
with the expression of Aurora kinases in 
glioblastomas 
Focal gains on 4p16.3 were also frequently identified 
in a subset of glioblastomas (Figure 5A).  We mapped the 
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Figure 2: High-resolution mapping of homozygous deletions detects DFFB, C1orf174, and LOC100133612 within 
secondary MDr on 1p36.32. (A) Chromosome 1 DK analysis of glioblastoma cell line H542 indicates a single homozygous deletion 
occurring at the 1p36.32 cytoband.  (B) High-resolution mapping depicts overlapping homozygous deletions from 3.0Mb to 5.5Mb coordinates 
on chromosome 1 (indicated by red bars). Copy number data includes tumor samples from our independent analysis plus the TCGA glioblastoma 
copy number data set.  RefSeq gene positions are indicated.  Genomic Q-PCR validation analysis (*) of H542, H561, and glioblastoma xenograft 
X397 confirms homozygous deletion.  Q-PCR primer location depicted by black boxes (Supplemental Table S5).Oncotarget 2010; 1: 265-277 www.impactjournals.com/oncotarget 269
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Figure 3: High-resolution mapping of homozygous deletions reveals ERRFI1 within the most frequent MDr on 
1p36.23. (A) DK analysis of chromosome 1 in glioblastoma cell lines H423 and H502 reveals a single homozygous deletion at 1p36.23.  (B) 
High resolution mapping depicts overlapping homozygous deletions from 6.0Mb to 10.0Mb coordinates on chromosome 1 (indicated by red 
bars). Copy number data include tumor samples from our independent analysis and the TCGA glioblastoma copy number data set.  RefSeq gene 
positions are indicated.  Validation by genomic Q-PCR copy number analysis (*) of H423, H502, and glioblastoma xenograft X298 confirms 
homozygous deletion.  Q-PCR primer location depicted by black boxes (Supplemental Table S6).Oncotarget 2010; 1: 265-277 www.impactjournals.com/oncotarget 270
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Figure 4:  ERRFI1 is silenced in glioblastomas and reduces cell migration in H423 glioblastoma cells. (A) Quantifica-
tion of ERRFI1 mRNA levels in glioblastomas (32 cell lines, 15 xenografts, and 15 primary tumors) by Q-PCR.  Results presented as fold expres-
sion relative to normal cortex control (indicated by red line).  Restoration of ERRFI1 expression in H423 cells results in decreased cell migration 
as measured by (B) wound healing assay and (C) trans-well migration assay (T-test, p<0.001).Oncotarget 2010; 1: 265-277 271 www.impactjournals.com/oncotarget
4p16 duplications in a data set of 430 glioblastomas.  The 
gains clustered in a minimal gained region centered on 
4p16.3 from 1.5 to 2.0Mb (Figure 5B), containing SLBP, 
TMEM129, TACC3, FGFR3 and LETM1, of which TACC3 
most commonly displayed gain of copy number.  A Q-PCR 
analysis of an independent panel of glioblastoma samples 
detected genomic duplications of TACC3 in 5 out of 101 
samples.  In addition, compared with its adjacent genes, 
SLBP, TMEM129 and FGFR3 at 4p16.3, we found that 
TACC3 displayed a predominant overexpression pattern 
in glioblastomas (Figure 6A, S1 D).
Dysregulation  of  the  human  Transforming Acidic 
Coiled Coil (TACC) genes is thought to be important in 
the development of several cancers. The three human 
TACC proteins, TACC1, TACC2, and TACC3, are core 
components of the centrosome and have non-overlapping 
functions in the normal cell and the cancer cell [27, 28].     
TACC1 overexpression promotes cellular transformation 
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Figure 5: High resolution mapping identifies TACC3 as the glioblastoma-targeted gene on 4p16.3. (A) Illumina Bead-
Chip analysis of chromosome 4 in glioblastoma primary tumor TB3837 reveals a single focal gain at 4p16.3. (B) High resolution mapping depicts 
overlapping gain of copy number from 1.5Mb to 2.1Mb coordinates on chromosome 4 (indicated by green bars). Copy number data includes tumor 
samples from our independent analysis and the TCGA glioblastoma copy number data set.  RefSeq gene positions are indicated.  Oncotarget 2010; 1: 265-277 272 www.impactjournals.com/oncotarget
in vitro [29] and in vivo  [30].    TACC2  (AZU-1)  is  a 
putative tumor suppressor in breast cancer [31].  TACC3 
expression is upregulated and associated with shorter 
median survival in patients with non-small-cell lung 
cancer  [32].    However,  TACC3  expression  is  reduced 
in ovarian and thyroid cancer [33, 34]. We therefore 
assessed  expression  of  the  TACC  genes  in  a  panel  of 
gliomas (WHO Grades I-IV) by Q-PCR (Figure 7).  We 
found  significant  overexpression  of  TACC3  in  Grade 
IV gliomas.  Conversely, TACC2 transcript levels were 
significantly downregulated in Grade IV gliomas.
TACC3 can be phosphorylated by Aurora-A kinase 
and plays an important role in mitosis [35-37].  Therefore, 
to  determine  the  correlation  of  TACC3  and  Aurora 
kinase  expression,  we  used  Serial  Analysis  of  Gene 
Expression (SAGE) [5] and TCGA expression data sets 
to evaluate TACC3 and Aurora kinase gene expression in 
glioblastomas (Figure 6B, 6C).  We found a significant 
expression correlation between TACC3  and  Aurora  A 
(correlation coefficient = 0.76), as well as between TACC3 
and Aurora B (correlation coefficient = 0.70) (Figure 6C). 
DIscUssION
While many of the most common copy number gains 
and deletions have been characterized in glioblastomas, 
the significance of many other genomic events remains 
unknown.  Utilizing an independent set of glioblastomas 
and publicly available data, in this study, we focused on 
the identification and characterization of genes on two 
frequently altered regions, 1p36 and 4p16.  We found 
that ERRFI1 is a potential glioblastoma-targeted tumor 
suppressor gene and TACC3 is a potential oncogene.  
Deletions in 1p36 have been previously reported in 
glioblastoma genomic studies, indicating that multiple 
tumor suppressors exist in this locus [19, 38-42].  In our 
analysis, we observed several regions of deletions across 
1p36.  However, the most striking and frequent deletions 
occur between the 5 and 10Mb coordinates on 1p36.23, 
centering on the candidate tumor suppressor ERRFI1.  
Deletion  of  ERRFI1  has been reported to activate 
EGFR and sustain MAPK signaling, resulting in tumor 
phenotypes in numerous tissues in ERRFI1  knockout 
mice [43-45]. ERRFI1 is also frequently deleted, 
mutated, or down-regulated in breast and lung cancers, 
as well as in glioblastomas[38, 42, 46].  In a recent 
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Figure 6: TACC3 is the predominant gene upregulated in 4p16.3 and correlates with Aurora kinase expression. 
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study, overexpression of ERRFI1 was shown to decrease 
proliferation in glioblastoma cells, binding EGFR with 
STX8, and driving internalized EGFR to late endosomes 
for degradation, whereas knockdown of ERRFI1 
expression resulted in increased tumor invasion [47].  Our 
biological data are consistent with these previous findings, 
showing that restoring ERRFI1 expression in an ERRFI1-
deficient  glioblastoma  cell  line  decreases  glioblastoma 
cell migration.  Our genetic and biological data, as well as 
data from other studies, suggests that ERRFI1 is another 
key component in the EGFR signaling pathway involved 
in glioblastoma development. 
Genomic alterations of 4p16.3 have been reported 
in several cancers, indicating the presence of one or 
more oncogenes [48-51].  Using an integrative genomic 
strategy, we have analyzed genes altered in the 4p16.3 
region in glioblastomas and revealed that TACC3 is 
the primary glioblastoma-targeted gene in this region.   
Furthermore, a TACC3 somatic mutation (p.E680K) was 
reported in one of 22 glioblastomas [5].  TACC3 has a 
conserved function to promote centrosomal microtubule 
assembly, a process which is often altered in cancer cells 
[27, 52]. Consequently, genetic silencing of TACC3 results 
in destabilized microtubules, defects in chromosome 
alignment, and mitotic defects [52-54].  
The Aurora  family  of  serine-threonine  kinases  is 
comprised of three members (A, B, and C) that cooperate 
with  many  other  proteins,  including  the TACC  family, 
to direct chromosome assembly and segregation during 
mitosis [27, 55-57].  Dysfunction of Aurora kinases can 
disrupt genomic integrity and lead to aneuploidy, mitotic 
arrest, and cell death.  Aurora A and B are of particular 
interest since they have been shown to be overexpressed 
in a broad range of human tumors and are often associated 
with poor outcome.   Thus, regulators of the mitotic spindle 
apparatus, including Aurora kinases and its substrates, are 
attractive targets for small-molecule therapeutics [35, 58-
60]. In our study, we found a strong correlation between 
Aurora  kinase  and  TACC3  expression,  indicating  that 
in  the Aurora  kinase/TACC  pathway,  the  dysregulated 
kinase and its substrate, may contribute synergetically to 
glioblastoma pathogenesis and could serve as targets for 
molecular-based intervention. 
MAtErIALs AND MEtHODs
tumor samples
DNA  samples  were  obtained  from  brain  tumor 
cell lines, xenografts and primary brain tumors. Brain 
tumor tissue samples were obtained from the Preston 
Robert Tisch Brain Tumor Center Biorepository at Duke 
University Medical Center by an IRB-approved protocol. 
All samples were obtained in accordance with the Health 
Insurance  Portability  and  Accountability  Act.  Frozen 
sections were made from each tumor sample and examined 
by light microscopy by a board-certified neuropathologist 
to ensure that more than 95% of each section consisted of 
tumor cells.  Normal patient DNA samples were obtained 
from  peripheral  blood.    Normal  adult  and  fetal  brain 
genomic DNA was obtained from BioChain Institute, Inc. 
(Hayward,  CA).    Samples  were  defined  as  pediatric  if 
taken from a patient between the ages of 0 and 19. 
Digital Karyotyping
We  generated  18  glioblastoma  DK  libraries. 
Additionally, we included 1 primary and 8 glioblastoma 
cell  line  DK  libraries  from  the  Cancer  Genome 
Anatomy  Project  [19]  (http://cgap.nci.nih.gov/SAGE/
DKViewHome).    Protocols  for  performing  DK  and 
software for the extraction and analysis of genomic 
Fig 7. Grade-specific TACC3 upregulation and TACC2 downregulation in gliomas.  (A) TACC3 and (B) TACC2 mRNA levels in a panel of 93 
glioma samples were assessed by Q-PCR.  Results presented as fold expression relative to normal cortex control.  I (WHO classification glioma 
Grade I), II(WHO classification glioma Grade I), III (WHO classification glioma Grade III), IV (WHO classification glioma Grade IV).
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tags are available at www.digitalkaryotyping.org [61].   
Experimental tag sequences were compared to predicted 
human genome virtual tags and were visualized by using 
SageGenie  DKView  (http://cgap.nci.nih.gov/SAGE/
DKViewHome).  Homozygous  deletions  were  screened 
by using a sliding window size of 150 virtual tags (~600 
kb in size).  Putative homozygous deletions were defined 
as events with a tag density ratio (observed tags/expected 
tags in window) of < 0.05.  Amplifications were identified 
using a sliding window size of 50 virtual tags (~200 kb in 
size).  Putative amplifications were defined as events with 
a tag density ratio of > 6.
High density sNP arrays 
Eighty-four glioblastoma samples were analyzed 
for copy number variation by utilizing HumanHap550-
Duo and Human610-Quad BeadChips with the Illumina 
Infinium Whole Genome Genotyping Assay.  Data was 
pre-processed to generate logR intensity ratios using 
Illumina  BeadStudio.      Data  was  converted  into  copy 
number calls and visualized by using Nexus Copy Number 
software (BioDiscovery, Inc., El Segundo, CA).
tcGA Data  
Genome-wide  Level  3  TCGA  copy  number  data 
was downloaded with the TCGA Data Portal Data Access 
Matrix  (http://cancergenome.nih.gov/dataportal)  from 
Hudson-Alpha Cancer Genome Characterization Center, 
Memorial Sloan Kettering Cancer Center, and Harvard 
Medical School-Dana Farber Cancer Institute.  Candidate 
deletions  were  defined  as  events  with  seg  mean  ≤  -1. 
Candidate gains were defined as events with seg mean ≥ 
0.4.  Events less than 30kb and events occurring in two 
or more tumors with identical start and stop positions 
were removed, because they were likely artifact or 
copy  number  polymorphisms.  Candidate  gene  TCGA 
expression data from the University of North Carolina 
and Broad Institute was downloaded with the TCGA Data 
Portal Data Browser.  Gene expression values from the 
TCGA database represent the ratio of tumor expression to 
normal expression. The expression value for a given gene 
for a given patient is the log2 ratio of the tumor expression 
of the gene in the patient to a synthetic normal sample. 
bioinformatic Analysis
Nexus Copy Number software (BioDiscovery, Inc) 
was used to visualize copy number data.  The following 
values were used for screening of genetic events of 
homozygous  loss  and  amplification:    Significance 
Threshold, 1×10-8; Min probes per segment, 2 ; Max 
contiguous probe spacing (Kbp), 1000 ; Gain, 0.5 ; Loss, 
-0.7. For identification of areas of duplication, the Nexus 
default settings were as follows: Significance threshold, 
1×10-6, Min probes per segment, 5; Max contiguous probe 
spacing (Kbp), 1000; Gain, 0.2.
Quantitative real-time Pcr 
The genomic DNA content and mRNA expression 
levels of genes of interest within tumor and normal cells 
were  quantified  by  quantitative  real-time  polymerase 
chain  reaction  (Q-PCR).    Genomic  DNA  from  normal 
blood cells served as controls, and genomic DNA content 
was normalized to that of Line-1. For mRNA expression 
measurement,  cDNA  from  normal  human  adult  cortex 
was used as the control and cDNA content was normalized 
to  that  of  GAPDH.    Primers  for  genomic  mapping  of 
1p36.32 and 1p36.23 are listed in Supplemental Table S5 
and Supplemental Table S6.  
Wound Healing Assay  
H423 glioblastoma cells were maintained in ZO+ 
media (Gibco, Carlsbad, CA) with 10% fetal calf serum 
(FCS). Cells were transfected with pCMV6-entry or 
pCMV6-ERRFI1. Cells were plated at 100% confluence 
in 6-well plates. The cell monolayer was wounded with a 
p1000 pipette tip and wound healing was documented at 
0, 6 and 24 hours by photographs.
transwell Migration Assay  
H423 cells were transfected with pCMV6-entry or 
pCMV6-ERRFI1, washed, and resuspended in serum-free 
media, then seeded into transwell membranes at 10,000 
cells per well with 5% FCS as a chemoattractant. After 
24 hours, cells were removed from the upper chamber 
then fixed in 100% methanol on the lower surface of the 
membrane and stained with crystal violet (2% solution in 
ethanol) and counted (experiment performed in triplicate 
wells,  12  fields  counted  per  well).  Statistical  analyses 
were conducted with PASW (SPSS) 18.0 (IBM, Armonk, 
North Castle, NY).
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